
Applying lessons of raw materials’ characterization and supply-chain control from the semiconductor industry allow more rigorous control of the biopharmaceutical manufacturing process.
Gary Dailey is vice-president, Global Marketing, Electronic Materials, at Avantor.
Published: November 1st 2019 | Updated: